UNDERSTAND YOUR SERIALIZATION OPTIONS AND THE LONG AND SHORT-TERM BENEFIT OF SWITCHING PROVIDERS
Until now, most regulations―including the Drug Supply Chain Security Act (DSCSA)―have required minimal system capabilities. In the coming months, serialization systems will be tested for their ability to handle aggregation data, facilitate integration with distribution (internal and third-party logistics providers), integrate with downstream customers and handle complicated regulatory reporting requirements, such as the European Union’s Falsified Medicines Directive (EU FMD) and the Russian Federal Law No. 425-FZ.
If you are a pharma manufacturer and/or CMO and would like to better understand your serialization options for global requirements, download this 60-minute webinar as we share OPTEL’s approach to system conversions. We discuss our tested methodology and real-life case studies, as well as the immediate and longer-term benefits of moving to the OPTEL serialization platform.